Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
IOBT
IOBT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IOBT News
IO Biotech Engages Raymond James as Financial Advisor Amid Workforce Reduction
Jan 30 2026
Newsfilter
Piper Sandler Downgrades IO Biotech to Neutral Amid Strategic Review
Jan 27 2026
Yahoo Finance
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
Jan 23 2026
NASDAQ.COM
IO Biotech Evaluates Strategic Alternatives Amid $30.7M Cash Position
Jan 22 2026
NASDAQ.COM
High Roller Technologies Inc Closes Direct Offering, Raises $25 Million
Jan 22 2026
Benzinga
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%
Jan 22 2026
NASDAQ.COM
IO Biotech (IOBT) Explores Strategic Alternatives to Maximize Shareholder Value
Jan 21 2026
seekingalpha
IO Biotech (IOBT) Explores Strategic Alternatives to Maximize Shareholder Value
Jan 21 2026
Globenewswire
Zentalis Pharmaceuticals (ZNTL) Surges 17.65% as Investors Renew Interest
Jan 12 2026
NASDAQ.COM
Post-Market Winners: Biotech and Med-Tech Stocks Rise on FDA Developments, Trial Clarity, and Merger Momentum
Dec 16 2025
NASDAQ.COM
IO Biotech Publishes Five-Year Survival Data for Melanoma Vaccine
Dec 15 2025
Globenewswire
IO Biotech Reports Five-Year Survival Data for Melanoma Vaccine
Dec 15 2025
Newsfilter
IO Biotech to Showcase Cancer Vaccine Progress at Two Major Healthcare Conferences
Nov 26 2025
Newsfilter
IO Biotech to Participate in Two Major Healthcare Conferences Showcasing Cancer Vaccine Progress
Nov 26 2025
Globenewswire
Reassessing Biotech Pipelines: The Valuation Indicator Investors Have Anticipated
Nov 20 2025
Globenewswire
IO Biotech, Inc. (IOBT) Receives Upgrade to Buy: Reasons Explained
Nov 19 2025
NASDAQ.COM
Show More News
